Sensible Biotechnologies
mRNA manufacturing in cells, Oxford
Makes naturally modified mRNA inside cells for next-generation mRNA medicines. It raised $47m in its Series A in October 2026. We can't read its job board yet.
Not found on the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
- FundingThe Recursive, 26 days agoSlovak Sensible Biotechnologies Secures €42M for Cell-Based mRNA Platform
- OtherBusiness Weekly, 27 days agoSlovakia government and EU contribute to Sensible Biotechnologies' $47m raise
- Partnerships & dealsBusiness Wire, 9 Jul 2025Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible’s Unique Cell-Based mRNA Design and Manufacturing Platform
- OtherBioSpace, 12 Jun 2025Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology